Navigation Links
Cadence Pharmaceuticals to Webcast October 7th Analyst Day
Date:9/30/2009

SAN DIEGO, Sept. 30 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that it will host a live webcast of its Analyst Day on Wednesday, October 7, 2009 at 11:30 a.m. Eastern Time. Cadence's senior management team, led by Ted Schroeder, President and Chief Executive Officer, will provide an overview of the clinical data and market opportunity for the Company's investigational product candidate, Acetavance(TM) (intravenous acetaminophen), which is currently under Priority Review by the U.S. Food and Drug Administration for the treatment of acute pain and fever.

Scheduled Analyst Day guest speakers include:

  • Eugene Viscusi, M.D., Director Acute Pain Management Service in the Department of Anesthesiology at Jefferson Medical College in Thomas Jefferson University, Philadelphia, Pennsylvania
  • Dan Benhamou, M.D., Professor of Anesthesia and Intensive Care and Chairman of Anesthesia at the Hospital de Bicetre, Kremlin Bicetre, France

The webcast will be available via the Investor Relations page on the Company's website at www.cadencepharm.com. A replay of the webcast will be archived on the company's website beginning approximately two hours following the live event.

In addition, Mr. Schroeder and other members of the Cadence management team will preside over the NASDAQ opening ceremony on Tuesday, October 6, 2009 at NASDAQ's MarketSite in Times Square in New York City. A live webcast of the ceremony will be available at

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
2. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
3. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
5. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
6. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
7. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
8. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
9. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
10. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
11. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces ... is available in its catalogue: ... Broadened Diagnostic Criteria and Growing Adult ... Patent Expirations ... to 2020 - Broadened Diagnostic Criteria ...
(Date:8/28/2014)... --  RapidForce , an innovative muscle support and pain ... professional tennis player John Isner . Currently the ... competitions to help with knee support. He is wearing ... US Open Tennis Championships. Fifteen times ... a revolutionary hybrid of a brace and kinesiology tape. ...
(Date:8/28/2014)... , Aug. 28, 2014 The Leukemia ... a partnership to advance an experimental cancer vaccine ... an asymptomatic stage of myeloma. The ... through which LLS forges collaborations with biotechnology companies ... OncoPep is developing a vaccine, PVX-410, ...
Breaking Medicine Technology:ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8America's top-ranked tennis player John Isner Joins Forces with RAPIDFORCE Physio Hybrid Shapes 2America's top-ranked tennis player John Isner Joins Forces with RAPIDFORCE Physio Hybrid Shapes 3America's top-ranked tennis player John Isner Joins Forces with RAPIDFORCE Physio Hybrid Shapes 4The Leukemia & Lymphoma Society Provides Equity Financing to OncoPep to Support Clinical Trial for Myeloma Vaccine 2
... Jan. 25, 2011 Mylan Inc. (Nasdaq: MYL ... agreement with Pfizer Inc. resolving litigation related to Caduet® Tablets, ... mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, ... 10 mg/80 mg, known generically as Amlodipine Besylate/Atorvastatin Calcium Tablets. ...
... 2011 eCareSoft recently launched eCS Inpatient EHR V1.2 ... for small and medium hospitals. eCS,s uniqueness is the ... management systems into a single web-based software solution. The ... reduced costs and simplified deployment. "eCS is ...
Cached Medicine Technology:Mylan Announces Caduet® Settlement Agreement 2eCareSoft Launches Comprehensive EHR for Small & Medium Hospitals 2
(Date:8/28/2014)... Albany, New York (PRWEB) August 28, 2014 ... is currently perceived with great interest among other healthcare ... due to the high demand in vaccine with respect ... also highly in demand due to an improved understanding ... individuals across the United States. It has led to ...
(Date:8/28/2014)... Port Washington, New York (PRWEB) August 28, 2014 ... law firm that has spent many years fighting to ... comments that the decision to provide coverage to WTC ... report released by the U.S. Government Accountability Office (GAO). ... Watch on August 25th, the report is entitled ...
(Date:8/28/2014)... AZ (PRWEB) August 28, 2014 Hastings ... that has been providing quality accident attorney services and ... The firm is proud to announce that it has ... settlement that has been valued at over half of ... and Hastings provides genuine discount attorney's fees that result ...
(Date:8/28/2014)... (HealthDay News) -- Having greater amounts of yellow pigment ... distant objects in hazy conditions, a new study reports. ... simulated hazy conditions in order to test the distance ... (also called macular pigment) in their eyes. The ... represents accumulations of the nutrients lutein and zeaxanthin, according ...
(Date:8/28/2014)... Genetic testing for multiple diseases and ... large reference laboratories as well as smaller providers ... to the genetic variants analyzed, the methods used, ... find the most appropriate laboratory providers for their ... these differences, Hayes, Inc. has added GTE Laboratory ...
Breaking Medicine News(10 mins):Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 2Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 3Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 2Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $23,400 On Settlement Of $540,000 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $23,400 On Settlement Of $540,000 3Health News:Eye Pigment May Help Vision in Hazy Conditions 2Health News:Hayes, Inc. Unveils Laboratory Comparison Tables for GTE Clients 2
... News) -- The time between the start of substance abuse ... than for women, a U.S. government report shows. Researchers ... the first time last year and found that the average ... were primarily being treated for was 15.6 years. The ...
... -- Medical researchers are demonstrating that Office of Naval ... mines can help doctors identify and classify cancer-related cells. ... professor at Duke University and developer of the technology. ... The problem that physicians encounter in analyzing images ...
... By Denise Mann HealthDay Reporter , THURSDAY, Oct. ... likely to cause skin cancer than previously believed. New research ... suggests that the main type of ultraviolet rays used in ... of skin that is most vulnerable to the cancer-causing changes caused ...
... Thomas Jefferson University biochemistry researchers have shown for the ... hormone doesn,t activate and repress genes as once thought. In ... a heme-binding receptor to repress the same genes during the ... the last 20 years, the nuclear receptor known as EcR/Usp ...
... Oct. 6 (HealthDay News) -- As many as one-third of Medicare ... of their life, a new Harvard study finds. But ... a tricky one that can only be decided by the doctor, ... medical director at the American College of Surgeons. Nor is ...
... Where you live could play a larger role in ... study by researchers from the Johns Hopkins Bloomberg School ... low-income neighborhood in Baltimore, Maryland and found that, with ... diabetes, obesity among women and use of health services ...
Cached Medicine News:Health News:Mine-hunting software helping doctors to identify rare cells in human cancer 2Health News:Tanning Beds May Be Even Riskier Than Thought 2Health News:Tanning Beds May Be Even Riskier Than Thought 3Health News:Nuclear receptors battle it out during metamorphosis in new fruit fly model 2Health News:Many Medicare Patients Get Surgeries in Last Year of Life: Study 2Health News:Place, not race, may be a larger determinant of health disparities 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: